Postpartum Depression — Causes, Symptoms, Screening & Treatment Guide — Symptoms, Causes & Treatment | MyMedicPlus

Postpartum depression (PPD), also called postnatal depression (PND), is a clinical depressive disorder arising within the first year after childbirth, distinct from the transient 'baby blues' (which affects 50-80% of mothers in the first 3-5 days postpartum and is self-limiting). PPD is defined by persistence of depressive symptoms (low mood, loss of interest, fatigue, sleep disturbance, feelings of inadequacy as a parent, and impaired bonding with the infant) lasting more than 2 weeks. It affects approximately 10-15% of mothers globally — equating to over 1 million women in the UK alone — and is the most common perinatal complication. PPD is also recognised in fathers and non-birth partners (4-10%). Without treatment, PPD can persist for months to years, impair maternal-infant attachment, and adversely affect the child's cognitive, emotional, and developmental outcomes. Despite being highly treatable, PPD is significantly underdiagnosed and undertreated due to stigma and inadequate screening.

PPD is multifactorial, with biological, psychological, and social contributors. Biological factors: abrupt postpartum withdrawal of oestrogen and progesterone (which were at high levels during pregnancy) triggers a neurobiological cascade affecting serotonin, dopamine, and GABA receptor sensitivity in predisposed women; sleep deprivation and circadian disruption compound this. Thyroid dysfunction (postpartum thyroiditis — affects 5-10% of women postpartum) can cause depressive symptoms and should be excluded. Psychological factors: personal history of depression or anxiety (strongest individual risk factor — 3-fold increased risk), previous PPD (risk of recurrence 25-40%), perfectionism and high expectations of motherhood, birth trauma (emergency caesarean, perineal injury, neonatal admission), and poor infant temperament. Social factors: lack of social support or partner support (single parenthood or relationship conflict is a major risk factor), financial stress, domestic violence, unwanted or unplanned pregnancy, and immigration status. Biological risk: preterm or medically complex infant, infant illness or NICU admission, fertility treatment pregnancy, and twin/multiple pregnancy.

Baby blues (normal, self-limiting): emotional lability (tearfulness), irritability, and anxiety in days 3-5 postpartum — resolves spontaneously within 10-14 days without treatment. Postpartum depression (persistent — seek assessment if symptoms last beyond 2 weeks or are severe): low or persistently sad mood, loss of interest or pleasure in the baby, excessive tiredness beyond normal new-parent fatigue, difficulty sleeping even when the baby sleeps, feeling of worthlessness or guilt ('I'm a bad mother'), difficulty concentrating or making decisions, withdrawing from family and friends, loss of appetite or overeating, irritability and anger, and feeling unable to cope. Impaired maternal-infant bonding: not feeling the expected love for the baby, feeling disconnected from or resentful of the infant — these symptoms are common and do not reflect the mother's character or genuine feelings. Intrusive thoughts: many mothers with PPD experience disturbing unwanted thoughts about harming the baby (ego-dystonic — distressing and contrary to the mother's wishes) — these must be discussed with a clinician and distinguished from postpartum psychosis (which involves command hallucinations and loss of insight). Postpartum psychosis: rare but severe emergency — confusion, hallucinations (particularly auditory command hallucinations), mania, paranoia, and rapid behaviour change occurring within days of delivery — requires emergency psychiatric admission.

PPD is diagnosed clinically using DSM-5 or ICD-11 criteria for a major depressive episode occurring with peripartum onset. Routine screening: the Edinburgh Postnatal Depression Scale (EPDS) is a validated 10-item self-report questionnaire completed at the 6-8 week postnatal check and at the health visitor review at 3-4 months — an EPDS score of 10 or above warrants clinical assessment; a score of 13 or above is likely PPD. NICE recommends asking two Whooley depression questions at each postnatal contact. Blood tests to exclude medical causes: thyroid function tests (postpartum thyroiditis — hypothyroid phase causes depression, fatigue, and weight gain), FBC (iron deficiency anaemia — very common postpartum, contributes to fatigue and mood), vitamin D level. Assessment must include: risk assessment for postpartum psychosis (hallucinations, thought disorder, marked behavioural change — emergency referral), risk assessment for suicidal ideation, assessment of infant bonding and safeguarding needs, social support assessment, and consideration of comorbid anxiety disorder. Partners and fathers should be offered screening.

Mild PPD: supported self-help (structured self-help materials, peer support groups, home visiting by a health visitor trained in PPD), and guided CBT or interpersonal therapy (IPT) through IAPT or specialist perinatal mental health services. Moderate PPD: CBT or IPT (NICE first-line — 16-20 sessions); antidepressants added if psychological therapy alone is inadequate. Severe PPD: combined antidepressants and psychological therapy; specialist perinatal mental health team involvement; consider mother and baby unit admission. SSRI pharmacotherapy: sertraline (Lustral) is the preferred SSRI in breastfeeding — lowest breast milk transfer and most safety data; paroxetine and fluoxetine are alternatives. All SSRIs used in breastfeeding require a risk-benefit discussion — benefits of treated maternal depression generally outweigh the small risk of drug exposure through breast milk. Brexanolone (synthetic GABA-A receptor modulator): FDA-approved IV infusion (first PPD-specific drug) — rapid onset of action within 2-3 days; currently not widely available outside the USA. Zuranolone (oral): approved 2023 — GABA-A modulator with 14-day course; significant antidepressant effect within 3 days. Mother-infant bonding interventions: video feedback interaction guidance (VIDE) and parent-infant psychotherapy improve bonding and infant outcomes alongside treatment of maternal PPD.

Untreated postpartum depression carries significant risks for both the mother and infant, making early recognition and treatment critically important. For the mother, untreated PPD can progress to severe major depressive disorder, postpartum psychosis (a psychiatric emergency requiring urgent hospitalisation, affecting 1-2 per 1,000 deliveries — characterised by delusions, hallucinations, rapid mood swings, and severe disorganisation), or chronic treatment-resistant depression. Suicide and infanticide, though rare, are among the most tragic complications of severe untreated postpartum psychiatric illness and account for a significant proportion of maternal mortality in the first postnatal year in high-income countries. For the infant, maternal depression impairs mother-infant bonding and attachment, leading to disrupted emotional, cognitive, and social development. Infants of depressed mothers show higher rates of insecure attachment, behavioural difficulties, language delays, and emotional dysregulation extending into childhood and adolescence. Breastfeeding difficulties are more common when PPD is untreated, and premature cessation of breastfeeding deprives the infant of its immunological and nutritional benefits. The partner and wider family are also significantly affected — partners of women with PPD have a 24-50% elevated risk of developing depression themselves, creating a compounding family mental health burden that requires holistic family-centred care.

Women with previous PPD or perinatal mental illness should have a documented perinatal mental health plan before delivery — prepared jointly with a perinatal psychiatrist, midwife, health visitor, and GP. Prophylactic SSRIs from delivery may be considered for women with previous severe PPD — discuss with a specialist. Ensure social support: discuss realistic birth and postnatal expectations with the partner and family before delivery. Partner involvement and shared infant care significantly reduce PPD risk and severity. Sleep preservation strategies (sharing night feeds with a partner, scheduled sleep windows). Midwife visits and health visitor contacts are key opportunities for screening and early intervention. Peer support programmes (mother and baby groups, PANDAS Foundation, NCT peer supporters) provide social connection and normalise struggles of new parenthood. Screening for antenatal depression (10-15% of pregnant women have depression — antenatal depression is the strongest predictor of PPD) and treating antenatal depression reduces the risk of PPD.

Seek emergency psychiatric care immediately if: the mother or baby is at immediate risk of harm, the mother is experiencing hallucinations, delusions, or severe disorganised thinking (postpartum psychosis — a psychiatric emergency requiring hospital admission), or there are clear thoughts of suicide with a plan or intent. Call 999, attend A&E, or call the crisis team. Contact your GP or midwife promptly (within 24-48 hours) if you have experienced persistent low mood for more than 2 weeks, intrusive distressing thoughts about harming yourself or the baby (these are common in PPD and do not mean you will act on them — but they need professional assessment), difficulty functioning or caring for the baby, or feelings of being disconnected from the baby. Do not wait to see if it improves — early treatment leads to faster recovery and better outcomes for mother, baby, and family. PPD is not a personal failure — it is a medical condition that responds well to treatment.